InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Wednesday, June 2, 2021

Information

Tags:

Economy of New York City, NASDAQ, Carotid artery stenosis, Stroke, GlobeNewswire, Finance, Financial markets, Service companies

Geotags:

Tel Aviv, , Il, ISRAEL

Organisation:

INSPIREMD INC.

Summary

Key Points:

TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.
Mr. Slosman will deliver his corporate presentation on June 9 at 11:30am ET, Track 3.
The Companys warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (Nasdaq).
Trading is expected to begin onJune 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.

TEL AVIV, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

Mr. Slosman will deliver his corporate presentation on June 9 at 11:30am ET, Track 3.

Investors can register to watch the presentation here.

Investors interested in scheduling a meeting with management should contact [email protected].

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes.

InspireMD’s common stock is quoted on the Nasdaq-CM under the ticker symbol NSPR. The Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have been approved for listing on The Nasdaq Capital Market (“Nasdaq”). Trading is expected to begin on June 8, 2021, under the symbols NSPRW and NSPRZ on the Nasdaq.

Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
[email protected]

CORE IR
[email protected]